Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0RC0H
|
||||
| Former ID |
DIB016806
|
||||
| Drug Name |
NPY Y5 antagonists
|
||||
| Synonyms |
NPY Y5 antagonists (obesity, depression); NPY Y5 antagonists (obesity, depression), GlaxoSmithKline
|
||||
| Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Investigative | [1] | ||
| Company |
GlaxoSmithKline plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1cccc(c1F)n1ccc(NC[C@@H]2CC[C@@]3(OC(=O)N(c4cccnn4)C3)<br />CC2)n1
|
||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7120-3 | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 308). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.